These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 37363103)
1. Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer. Lopez E; Hidalgo S; Roa E; Gómez J; Hermansen Truan C; Sanders E; Carrasco C; Pacheco R; Salazar-Onfray F; Varas-Godoy M; Borgna V; Lladser A Oncoimmunology; 2023; 12(1):2225291. PubMed ID: 37363103 [TBL] [Abstract][Full Text] [Related]
2. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells. Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754 [TBL] [Abstract][Full Text] [Related]
3. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12. Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116 [TBL] [Abstract][Full Text] [Related]
4. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine. Cha SE; Kujawski M; J Yazaki P; Brown C; Shively JE Oncoimmunology; 2021 Mar; 10(1):1899469. PubMed ID: 33796409 [TBL] [Abstract][Full Text] [Related]
5. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. Zhang E; Yang P; Gu J; Wu H; Chi X; Liu C; Wang Y; Xue J; Qi W; Sun Q; Zhang S; Hu J; Xu H J Hematol Oncol; 2018 Aug; 11(1):102. PubMed ID: 30103775 [TBL] [Abstract][Full Text] [Related]
7. Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma. Zhang C; Wang L; Zhang Q; Shen J; Huang X; Wang M; Huang Y; Chen J; Xu Y; Zhao W; Qi Y; Li Y; Ou Y; Yang Z; Qian C Front Immunol; 2023; 14():1182409. PubMed ID: 37304295 [TBL] [Abstract][Full Text] [Related]
8. Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30 Hombach AA; Rappl G; Abken H Mol Ther; 2019 Oct; 27(10):1825-1835. PubMed ID: 31331813 [TBL] [Abstract][Full Text] [Related]
9. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T. Erickson TA; Shih YP; Fass J; Jang M; Tran E Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601 [No Abstract] [Full Text] [Related]
13. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors. Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342 [TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy. Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445 [TBL] [Abstract][Full Text] [Related]
15. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells. Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289 [TBL] [Abstract][Full Text] [Related]
16. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models. Huang B; Luo L; Wang J; He B; Feng R; Xian N; Zhang Q; Chen L; Huang G Oncoimmunology; 2020; 9(1):1684127. PubMed ID: 32002297 [TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]
18. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies. Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A Front Immunol; 2021; 12():665970. PubMed ID: 34475869 [TBL] [Abstract][Full Text] [Related]
19. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA Zhang C; Wang Z; Yang Z; Wang M; Li S; Li Y; Zhang R; Xiong Z; Wei Z; Shen J; Luo Y; Zhang Q; Liu L; Qin H; Liu W; Wu F; Chen W; Pan F; Zhang X; Bie P; Liang H; Pecher G; Qian C Mol Ther; 2017 May; 25(5):1248-1258. PubMed ID: 28366766 [TBL] [Abstract][Full Text] [Related]
20. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. Bajor M; Graczyk-Jarzynka A; Marhelava K; Burdzinska A; Muchowicz A; Goral A; Zhylko A; Soroczynska K; Retecki K; Krawczyk M; Klopotowska M; Pilch Z; Paczek L; Malmberg KJ; Wälchli S; Winiarska M; Zagozdzon R J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35078921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]